Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...

For oral medications that prevent new HIV infection to be effective, the patient must take certain actions, including ...

Health experts say lenacapavir could reduce the number of global HIV infections significantly. But it needs to be cheaper to ...

A recent phase 3 trial found that twice-yearly injections of Lenacapavir reduce the risk of contracting HIV by 96%. | Drug ...

A new HIV prevention method, Lenacapavir, administered as a twice-yearly injection, has demonstrated superior results ...

Scientists have developed Lenacapavir, a twice-yearly injection that cuts HIV infection risk by 96% in groundbreaking trials.

The shot was 100% effective in preventing HIV infections in a study of women, and results published Wednesday show it worked ...

In the PURPOSE 2 trial, lenacapavir offered almost complete protection to cisgender men, transgender women, transgender men, ...

Lenacapavir, a new twice-yearly injection, offers 96% HIV prevention efficacy, surpassing daily oral PrEP. For oral ...

Gilead Sciences has announced the outcomes from the Phase III PURPOSE 2 trial evaluating lenacapavir for HIV prevention.